Efficacy of butyrate in the treatment of mild to moderate Crohn's disease

A. Di Sabatino, P. Cazzola, R. Ciccocioppo, R. Morera, P. Biancheri, L. Rovedatti, L. Cantoro, A. Vanoli, F. P. Tinozzi, S. Tinozzi, G. R. Corazza

Research output: Contribution to journalArticlepeer-review


Background: Butyrate exerts anti-inflammatory effects in experimental colitis and in lamina propria mononuclear cells of patients with Crohn's disease. Aims: To assess the safety and efficacy of butyrate in Crohn's disease. Patients: Thirteen patients with mild to moderate Crohn's disease were treated with enteric-release sodium butyrate tablets at a dosage of 4 g/day for eight weeks. Methods: Before and after treatment, patients underwent coloscopy with evaluation of the clinical activity of their disease, systemic inflammation index and mucosal expression of interleukin (IL)-1β, IL-6, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and nuclear factor (NF)-κB. Results: Of the nine patients (69%) responding to treatment, 7 (53%) exhibited complete response and 2 exhibited partial response. Endoscopic and histological evaluation scores were significantly improved (p <0.05) and significant reductions were seen after treatment in white cell count, erythrocyte sedimentation rate (ESR), mucosal concentrations of NF-κB and IL-1β (p <0.05). Conclusions: Oral administration of butyrate may be effective in inducing clinical improvement or remission in patients with Crohn's disease.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalDigestive and Liver Disease Supplements
Issue number1
Publication statusPublished - Sep 2007


  • Butyrate
  • Crohn's disease
  • Cytokine
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Efficacy of butyrate in the treatment of mild to moderate Crohn's disease'. Together they form a unique fingerprint.

Cite this